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Abstract
Ischemic acute renal failure (ARF) is a highly complex disorder involving renal vasoconstriction, filtration failure, tubular
obstruction, tubular backleak and generation of reactive oxygen species. Due to this complexity, the aim of our study was to
explore effects of Angiotensin II type 1 receptor (AT1R) blockade on kidney structure and function, as well as oxidative stress
in spontaneously hypertensive rats (SHR) after renal ischemia reperfusion injury. Experiments were performed on
anaesthetized adult male SHR in the model of ARF with 40 minutes clamping the left renal artery. The right kidney was
removed and 40 minutes renal ischemia was performed. Experimental groups received AT1R antagonist (Losartan) or
vehicle (saline) in the femoral vein 5 minutes before, during and 175 minutes after the period of ischemia. Biochemical
parameters were measured and kidney specimens were collected 24h after reperfusion. ARF significantly decreased
creatinine and urea clearance, increased LDL and lipid peroxidation in plasma. Treatment with losartan induced a significant
increase of creatinine and urea clearance, as well as HDL. Lipid peroxidation in plasma was decreased and catalase enzyme
activity in erythrocytes was increased after losartan treatment. Losartan reduced cortico-medullary necrosis and tubular
dilatation in the kidney. High expression of pro-apoptotic Bax protein in the injured kidney was downregulated after
losartan treatment. Our results reveal that angiotensin II (via AT1R) mediates the most postischemic injuries in hypertensive
kidney through oxidative stress enhancement. Therefore, blockade of AT1R may have beneficial effects in hypertensive
patients who have developed ARF.
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Introduction
Acute renal failure (ARF) has a multifactorial causality, but the
mechanism of pathogenesis and the development of this disease
are still incompletely defined. Ischemia/reperfusion injury (IRI)
frequently occurs in several clinical situations including renal
transplantation, suprarenal procedures of aorta and certain
hypotensive states [1].
It is known from experimental studies that both ischemia and
reinstitution of blood flow in the kidney injury generate reactive
oxygen species (ROS), during and after reperfusion. Under normal
conditions, antioxidant defense system neutralizes cellular effects
of oxygen-free radicals, but due to reperfusion in ischemic tissue,
the protective capacity of these scavengers is overwhelmed by
rapid generation of ROS. Renal dysfunction caused by overpro-
duction of ROS in IRI is closely associated with cell membrane
peroxidation, mitochondrial dysfunction, inhibition of protein
synthesis, DNA damage and inhibition of the antioxidant system
[2,3]. Therefore, the main target of IRI therapies should be found
in the pharmacological approach for decreasing the renal
oxidative stress.
Angiotensin II (Ang II), as one of the main vasoactive signaling
molecule, is involved in the generation of ROS. Overproduction of
Ang II during the ischemic ARF [4,5] participates in increased
expression and activity of one of the major ROS generators,
NADPH oxidase [6]. Also, it is well known that the increased
production of Ang II occurs in hypertensive conditions [7].
Beyond intrarenal vasoconstriction, high level of Ang II has
harmful effect on necrotic and apoptotic changes in kidney tissue
during reperfusion period, as well [3,8]. Furthermore, Ang II
down-regulates the SR-BI HDL receptor in proximal tubular cells
[9], therefore abolishes the protective HDL effects on postischemic
kidney [10].
Ratio between expression of pro-apoptotic (i.e., Bax) and anti-
apoptotic (i.e., Bcl-2) genes is crucial for cell surviving [11]. During
kidney IRI, expression of these proteins in renal tissue is disturbed
[3]. Further, it has been reported that Losartan has relevance on
Bax and Bcl-2 expression in hypertension [11].
Taking all together, the goal of our research was to explain a
relation between the increased oxidative stress and blockade of
Ang II type 1 receptor (AT1R) receptor during the postischemic
ARF in hypertension.
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Materials and Methods
In our study we used 24 weeks old male spontaneously
hypertensive rats (SHR), weighing about 300 g, which were bred
at the Institute for Medical Research, University of Belgrade,
Serbia, and fed with a standard chow for laboratory rats
(Veterinarski zavod, Subotica, Serbia).
Ethics Statement
The experimental protocol was approved by the Ethic
Committee of the Institute for Medical Research, University of
Belgrade, Serbia (No. 0148.1/10), according to the National Law
on Animal Welfare ("Službeni Glasnik" no. 41/09) that is
consistent with guidelines for animal research and principles of
the European Convention for the Protection of Vertebrate
Animals Used for Experimental and Other Purposes (Official
Daily N. L 358/1-358/6, 18, December 1986) and Directive on
the protection of animals used for scientific purposes (Directive
2010/63/EU of the European Parliament and of the Council,
22.9.2010.).
Experimental protocol
Animals were divided into the following groups: sham-operated
rats (SHAM, n = 7), rats with ARF (ARF, n = 7) and animals
received AT1R antagonist Losartan (DUP 153, Du Pont,
Wilmington, DE, USA) after ARF induction (ARF+LOS, n = 9).
For surgical procedure, all rats were anaesthetized with 35 mg/
kg b.m. sodium pentobarbital. ARF was induced by right kidney
nephrectomy and atraumatic occlusion of left renal artery for 40
minutes. SHAM and ARF rats received vehicle (saline, 4 ml)
infusion, while ARF+LOS group received Losartan (10 mg/kg
b.m dissolved in 4 ml saline) infusion, in the femoral vein 5
minutes before, during and 175 minutes after clamping. After
infusion, abdominal incision was closed by several sutures and
SHR were placed into metabolic cages for 24 h urine collection,
having free access to water and chow.
Blood pressure measurements
Mean arterial pressure (MAP) was measured in anaesthetized
rats. Left femoral artery was canulated by PE–50 catheter (Clay-
Adams Parsippany, NY, USA) and connected to the physiological
data acquisition system (9800TCR Cardiomax III-TCR, Colum-
bus, OH, USA). Measurements were performed before and
24 hours after reperfusion.
Biochemical measurements 24 h after reperfusion
After 24 h urine collection all animals were anaesthetized
(35 mg/kg b.m. sodium pentobarbital, i.p.) and blood samples
were taken for determination of creatinine (PCr), urea (PU),
cholesterol, HDL and triglyceride levels in plasma. Lithium-
heparin (Li-heparin, Sigma, USA) was used as an anticoagulant.
24 h urine samples were used for determination of urine creatinine
(UCr) and urea (UU) concentrations. All biochemical parameters
were measured using an automatic COBAS INTEGRA 400 plus
(Hoffmann-La Roche, Germany) analyzer. LDL was calculated
from Friedewald equation. Creatinine (CCr) and urea (CU)
clearances were calculated according to standard formula and
normalized to body weight. After blood samples collection,
animals were sacrificed by pentobarbital overdose injection.
Oxidative stress parameters
In order to determine the degree of lipid peroxidation (LP), the
concentration of thiobarbituric acid reactive substances (TBARS)
in plasma was measured [12]. Erythrocytes catalase (CAT),
glutathione reductase (GR), superoxide dismutase (SOD) and
glutathione peroxidase (GSH-Px) activities were measured by
spectrophotometry, according to previously described methods
[13–16].
Morphological and immunohistological examination
At the moment of sacrificing, the left kidney was taken for the
morphological analysis. Renal tissue was prepared as described
previously [8], and stained by hematoxiline eosine (H&E) and
periodic acid-Schiff (PAS). Intensity and spread of tubular
necrosis, number of intra-luminal cast formations, swelling and
vacuolization of cells, loss of luminal membrane or brush borders,
tubular dilatation, interstitial oedema and separation of cells from
tubular basal membrane were semi-quantitatively evaluated as
described previously [8]. The level of each manifestation was
graded with 1 for low, 2 for moderate, 3 for high, and 0 for the
lack of manifestation. The sum of these changes represented the
histopathological score.
For investigation of Bax and Bcl-2 expression paraffin, sections
were treated by microwave for 20 min at 400 W in citrate buffer
(pH 6.0) after deparaffinization and dehydration. After antigen
retrieval, samples were incubated with Bax (dilution 1:250,
Millipore, Billerica, MA) and Bcl-2 (dilution 1:200, Millipore,
Billerica, MA) antibodies for 1 hour at room temperature. The
EnVisionTM staining method (DAKO) was performed, followed
by counterstaining with hemalaun (Merck). Negative controls were
performed by omitting the first antibody. The slides were
evaluated using the light microscope BX53 (Olympus).
Statistical analysis
The results are shown as the mean with the standard error of
the mean. We used the single-sided Student’s t-test for two-
samples of equal variance, and value p,0.05 was considered
notable (Microsoft Excel 2010).
Results
Blood pressure measurements
There was no significant MAP difference between groups before
ARF induction. MAP was significantly decreased in ARF
compared to SHAM as well as in ARF+LOS vs. ARF group
24 hours after reperfusion (Figure 1).
Biochemical parameters
Biochemical parameters are presented in Table 1. CCr and CU
were significantly lower in ARF group vs. SHAM. Treatment with
Losartan markedly increased CCr and CU in comparison to ARF
group. There were non-significant differences between triglycer-
ides and total cholesterol level in experimental groups. Plasma
LDL was significantly increased in ARF group compared to
SHAM, and Losartan reduced it, not significantly (p = 0.054), but
almost near a value as in SHAM. HDL cholesterol was
significantly higher in ARF+LOS group, compared to level in
ARF group.
Oxidative stress parameters
SOD, GSH-Px and GR activity, were not different between
groups (Table 2). ARF group showed significantly higher TBARS
level compared to SHAM operated animals, with marked, but not
significant, decrease of CAT activity. Losartan infusion resulted in
both a significant increase of CAT activity and the decline of
TBARS compared to ARF alone (Table 2).
Losartan and Postischemic Hypertensive Kidney
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Histological studies
There were significant differences in pathomorphological
parameters between experimental groups. Figure 2A shows the
normal appearance of glomeruli, interstitium, tubules and blood
vessels in SHAM operated animals. Only in a few kidney
specimens there was a less number of PAS positive casts in the
lumen of the tubules. The kidneys of animals with ARF showed
dilatation of certain segments of the proximal and distal tubules,
with or without loss of brush-border. The most notable changes
were present in the cortico-medullary zone, where the broad areas
of tubular necrosis and a large number of PAS positive casts in the
collecting ducts were observed. The intensity of interstitial edema
in this group varies from sample to sample (Figure 2B). In
Losartan treated animals, less damage is noticed in comparison to
renal tissue of ARF animals. Tubular dilatation is smaller or even
absent in some kidney specimens. In the cortico-medullary zone,
tubular necrosis is reduced. Interstitial edema is rarely observed. In
addition, the number of tubular casts in the renal medulla is lower,
compared to ARF animals (Figure 2C). Histopathological score
was shown in Figure 2D.
Anti-apoptotic Bcl-2 protein expression was absent or very
slightly present in proximal tubular cells of SHAM (Figure 3A),
but it was significantly higher in animals with ARF (Figure 3C).
Treatment with Losartan markedly reduced the expression of Bcl-
2 protein on proximal tubules, indicating lower degree of
apoptotic lesions in them (Figure 3E).
Bax protein had slightly to moderate expression, mainly on
some distal tubules of cortico-medullar zone, in SHAM
(Figure 3B). The expression of the Bax protein is almost
completely absent in the cortex of these animals. However, the
kidneys of animals with ARF showed the expression of Bax
proteins on some cortical proximal tubules, in addition to intensive
expression on distal cortico-medullary tubules (Figure 3D).
Losartan treatment leads to decrease of Bax protein expression
after IRI (Figure 3F). There is almost complete absence of Bax
protein expression particularly in cortex, with slight presence on
distal tubuli.
Discussion
This study, for the first time, demonstrated that in combined
model of hypertension and postischemic ARF, kidney oxidative
injuries are strongly mediated by Ang II.
Bayrak et al. point to increased plasma LP in renal IRI [17]. In
SHR, the AngII-AT1R mediated effects on kidney ROS are
Figure 1. Mean arterial pressure in experimental groups before and 24 h after reperfusion. SHAM, n = 7; ARF, n = 7; ARF+LOS, n = 9 (n-
number of animals). Data are presented as mean 6 SEM (###p,0.001 compared with SHAMl; ***p,0.001 compared with ARF).
doi:10.1371/journal.pone.0096353.g001
Table 1. Biochemical parameters in experimental groups 24 h after renal ischemia/reperfusion injury.
SHAM (n = 7) ARF (n = 7) ARF+LOS (n = 9)
Creatinine clearances (ml/min/kg) 6.5060.99 0.2960.13### 1.7060.20***
Urea clearances (ml/min/kg) 2.3860.28 0.1060.05### 0.6460.09***
Cholesterol (mmol/l) 1.3260.09 1.5360.09 1.5360.12
Triglycerides (mmol/l) 0.8960.10 0.8660.08 0.9760.08
HDL (mmol/l) 0.6160.03 0.5760.05 0.7560.02**
LDL (mmol/l) 0.360.08 0.5760.08# 0.3460.10
#p,0.05, ###p,0.001 compared with SHAM level; **p,0.01, ***p,0.001 compared with ARF. Data are presented as mean 6 SEM. n-number of animals.
doi:10.1371/journal.pone.0096353.t001
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associated with NADPH oxidase overexpression, even before the
onset of hypertension [18]. Blockade of RAS with angiotensin
converting enzyme (ACE) inhibitor, Captopril, [19] decreased
oxidative stress of these rats. Also, AT1R antagonist, Candesartan,
significantly attenuate LP in humans [20]. Our results are
consistent with previously mentioned, because Losartan reduced
TBARS, therefore, at least partly, protects target cells from LP
injury. Also, the improved antioxidant defense, due to increased
CAT activity after losartan treatment, in our study, further
suggests that AT1R blockade could attenuate oxidative stress in
SHR with induced postischemic ARF. Losartan can also prevent
the increased concentration of H2O2 caused by Ang II infusion
[21]. In addition, it was shown that eight-week Losartan treatment
leads to an increase of CAT activity in damaged cardiac tissue of
Sprague-Dawley rats [22]. It is well-known that hydroxyl radical,
one of the most reactive oxygen species, as a product of H2O2
degradation (Fenton’s reaction), has an important role in LP, but
CAT decomposes H2O2 to both electro-neutral H2O and O2
molecules. In our model of ischemic ARF in SHR, increased CAT
activity and reduced LP, due to AT1R antagonism, indicate a
close connection between RAS and oxidative stress. On the other
hand, activity of other antioxidant enzymes SOD, GR, and GSH-
Px were unaffected by ARF or losartan treatment, indicating that
the activity of these enzymes is not directly mediated by RAS in
the presented experimental setting.
Table 2. Oxidative stress parameters in experimental groups 24 h after reperfusion.
SHAM (n = 7) ARF (n = 7) ARF+LOS (n = 9)
pTBARS (nmol/ml) 7.2860,76 10.5460.52## 7.2160.36**
eCAT (mmol H2O2/min) 22.1566.05 14.3262.91 22.5763.25*
eGR (mmol NADPH/min/g Hb) *103 5.661.8 4.961.2 7.462.2
eGSH-Px (mmol NADPH/min/g Hb) 185.1659.4 152.44627.1 188.6631.1
eSOD (U/g Hb)*103 1.660.4 1.560.5 2.160.3
##p,0.01 compared with SHAM level; *p,0.05, **p,0.01 compared with ARF. Data are presented as mean 6 SEM; n-number of animals; p-plasma; e- erythrocyte.
doi:10.1371/journal.pone.0096353.t002
Figure 2. Histology of the kidney 24 h after reperfusion. (A) normal shape of the glomerulus and tubulointerstitium in the sham-operated
animals (B) proximal tubular dilatation and necrosis, PAS-positive casts in the ARF control group (C) moderately intensive tubular necrosis in Losartan
treated rats, reduced tubular dilatation and less number of PAS-positive casts (D) Histopathological score in experimental groups 24 h after
reperfusion. SHAM, n = 7; ARF, n = 7; ARF+LOS, n = 9 (n-number of animals). Data are presented as mean 6 SEM (###p,0.001 compared with SHAMl;
***p,0.001 compared with ARF).
doi:10.1371/journal.pone.0096353.g002
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In our study blood pressure was moderately reduced after ARF
induction, similar to the results performed in the model of glycerol
induced ARF. In this model Bowmer [23] considered high uremia
influence on autonomic nervous system (diminished a1 adrenore-
ceptors sensitivity) as a cause of blood pressure reduction. Further,
in the present study losartan as a potent vasodilator additionally
decreased MAP in treated rats compared to control ARF. This
suggests that Ang II strongly participates in blood pressure control
after renal ischemia in SHR. Our results were similar to
Miloradović et al. [8] who showed that losartan reduced MAP
in L-NAME (3 mg/kg b.m.) induced hypertensive Wistar rats after
ARF induction.
Previous results of our group showed that neither ACE inhibitor
nor competitive inhibitor of xanthine oxidase were able to
ameliorate the decline of glomerular filtration in ARF hypertensive
rats [24]. Kontogiannis and Burns [4] showed that blockade of
AT1R with Losartan accelerated the recovery of renal function,
leading to a significant decrease in serum creatinine of male
Sprague-Dawley rats, with 60 minutes bilateral occlusion of renal
hilum. Furthermore, Miloradović et al. [8] showed that Losartan
led to a slight GFR improvement in postischemic kidney of Wistar
rats after moderate blockade of NO synthesis. In the present study,
Losartan significantly increased GFR 24 h after renal reperfusion,
in addition to previously described haemodynamic benefits [25].
This confirms that Ang II plays a critical role in the regulation of
glomerular filtration in disturbed hypertensive vasoactive milieu
after IRI. Low CU, another marker of altered GFR in ARF, was
also ameliorated with losartan.
Protective effects of HDL have been found in animal studies, as
well as in patients [10,26]. Thiemermann et al [10], showed that
bolus of HDL could improve renal function and structure after
ischemic ARF in Wistar rats. In our study, blockade of AT1R with
losartan resulted in a significant increase of plasma HDL. It was
shown that Ang II downregulates protective HDL receptors on
tubular cells via AT1R [9], therefore, AT1R blockade could have
beneficial effects. Furthermore, due to antioxidative properties of
AT1R blockade, HDL appears as a main fraction in total plasma
cholesterol content.
Figure 3. Bcl-2 and Bax expression in kidney tissue 24 h after reperfusion. (A) almost absence of Bcl-2 expression on proximal tubules of
sham operated animals (B) Bax protein in the sham-operated animals exclusively on distal tubule (C) up-regulated Bcl-2 expression on tubular cells in
ARF animals (D) widely and strong expression of Bax expended on proximal tubular cells in ARF animals (E) slight expression of Bcl-2 protein in group
treated with losartan (F) reduced Bax protein expression after ischemic-reperfusion injury in losartan treated rats.
doi:10.1371/journal.pone.0096353.g003
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Morphological changes in the kidney tissue represent the best
portrait of ARF development [27,28]. The most notable changes
in the ischemic kidney that can be seen by light microscopy are
broad areas of necrosis, the most common in the cortico-medullary
zone, brush border loss and a large number of PAS positive casts
in the renal medulla [27,29]. Morphological changes in the
kidneys isolated from rats with induced ischemic ARF, exactly
correspond to the previous description. In addition to these
changes, the dilations of certain segments of the proximal and
distal tubules, with or without loss of brush-border were observed.
Our results clearly indicate that Losartan, used to block AT1R
in the early stages of ischemic ARF in hypertension, has beneficial
effects on renal morphological structure. Lesions of tubular
epithelial cells (the main damage occurred during ARF) are less
severe in Losartan treated rats. This histological finding suggests a
positive effect of Losartan, which is further consistent with the
improvement of both systemic and renal artery hemodynamic
parameters [25], as well as the biochemical parameters of kidney
function improvement in the present study. Heeb [30] showed a
protective effect of Losartan on kidney morphology in rats with
gentamicin-induced ARF. The other study also showed a
beneficial effect of Losartan on the kidney morphology in rats
with malignant hypertension [31].
The survival and regeneration of cells are important factors in
the recovery of renal function in ARF. The relationship between
Bax and Bcl-2 expression can be a good predictor of renal
recovery potential after ischemic damage in ARF. The study of
Gobe et al. [3] showed the increased expression of Bax and Bcl-2
in the kidney, 24 h after 30 minutes bilateral renal ischemia in
Sprague Dawley rats. Bax was increased in both the proximal and
distal tubules, and Bcl-2 protein was upregulated in tubular
epithelial cell. These results are consistent with the results we
obtained in this study, where ischemic ARF leaded to increased
expression of Bax in SHR. On the other hand, in Ang II induced-
hypertension, Losartan reduced the expression of Bax in the
kidney, but did not affect Bcl-2 level [32]. In our experimental
study AT1R blockade significantly reduces the expression of Bax,
as well as Bcl-2, after IRI. Considering that Ang II-induced
apoptosis of mesangial and proximal tubular cells is associated
with increased generation of ROS [18], our findings suggest that
the RAS blockade slows cell death in postischemic hypertensive
kidney, thus helps kidney to establish better function.
Conclusions
From our results we can conclude that Ang II plays a significant
role in the development and maintenance of experimental
postischemic ARF in the hypertensive rats and partly contribute
to the blood pressure increasing Also, these results suggest that the
intensity of tubular injury could be reduced in the hypertensive
patients who are on therapy with AT1R blockers, and that these
patients have no particular risks of kidney function deterioration
during the ischemic ARF episode. However, our hypothesis
requires further complex and comprehensive clinical research for
definite conclusions about AT1R antagonist usage in ARF
hypertensive patients.
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